Channel Therapeutics CORP 8-K filings

Pelthos Therapeutics announced strong second quarter 2026 financial results, with Zelsuvmi net product revenue increasing 45% quarter-over-quarter, alongside updates on pipeline development and financing.

Pelthos Therapeutics Inc. announced that previously issued financial statements for the quarter ended March 31, 2026, must be restated due to a misapplication of fair value measurement standards for convertible debt.

Pelthos Therapeutics announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026.

Pelthos Therapeutics Inc. announced a change in its independent registered public accounting firm and detailed the separation terms for its former CFO.

Pelthos Therapeutics Inc. reported first quarter 2026 financial results, highlighting a 17% quarter-over-quarter increase in ZELSUVMI net product revenue and providing updates on its expanding sales force and strategic acquisitions.

Pelthos Therapeutics announced its CEO will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026.

Pelthos Therapeutics Inc. announced the appointment of John M. Gay as Chief Financial Officer, effective April 10, 2026, succeeding Francis Knuettel II.

Pelthos Therapeutics reports strong ZELSUVMI sales growth and strategic acquisitions, positioning for future revenue expansion.

Pelthos Therapeutics Inc. has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance to accelerate commercialization of its infectious disease product portfolio.

Pelthos Therapeutics Inc. announced changes to non-employee director compensation and provided a corporate presentation detailing strong early Zelsuvmi launch uptake and new product acquisitions.

Pelthos Therapeutics Inc. has acquired Xeglyze, an FDA-approved topical treatment for head lice, from Hatchtech Pty Ltd. for $1.8 million, expanding its commercial portfolio.

Pelthos Therapeutics Inc. expanded its Board of Directors to eight members and appointed seasoned finance executive Andrew J. Einhorn, effective December 23, 2025.

Pelthos Therapeutics stockholders approved all proposals at the 2025 Annual Meeting, including director elections, a waiver for convertible notes, and auditor ratification.

Pelthos Therapeutics Inc. announced strong third-quarter fiscal 2025 financial results, with its ZELSUVMI launch exceeding expectations and the acquisition of XEPI expanding its dermatology portfolio.

Pelthos Therapeutics announced an $18 million convertible notes financing and the acquisition of U.S. commercialization rights for Xepi, an FDA-approved impetigo treatment, aiming for a late 2026 re-launch.

Pelthos Therapeutics Inc. announced strong early commercial uptake for its newly launched Molluscum contagiosum treatment, Zelsuvmi, alongside a robust pipeline of therapeutic candidates.

Pelthos Therapeutics Inc. (formerly Channel Therapeutics) reported significantly increased net losses and operating expenses for LNHC, Inc. following its merger, despite the recent FDA approval and commercial launch of ZELSUVMI.

Pelthos Therapeutics announced its CEO and CFO will present at the Wells Fargo 2025 Healthcare Conference, providing updates on its ZELSUVMI commercial launch and product pipeline.

Pelthos Therapeutics reports financial results for legacy operations for Q2 2025 and provides a business update, highlighting the successful launch of ZELSUVMI and completion of a merger and private placement.

Pelthos Therapeutics Inc. (formerly Channel Therapeutics Corporation) has successfully completed its merger with LNHC, Inc., secured $50.1 million in private placement financing, and is set to launch its lead product ZELSUVMI for molluscum contagiosum.

Channel Therapeutics acknowledges a 'going concern' emphasis in its 2024 audit opinion to comply with NYSE American listing rules, as previously disclosed in its Form 10-K.

Channel Therapeutics Corporation will merge with Ligand Pharmaceuticals' Pelthos Therapeutics, supported by a $50 million private placement, to focus on commercializing ZELSUVMI for molluscum contagiosum.

Channel Therapeutics Corporation has entered into a material agreement, issuing an unsecured promissory note for $325,000 to 3i, L.P. to bolster its financial position.

Chromocell Therapeutics Corporation has changed its name to Channel Therapeutics Corporation and reincorporated in Nevada, while also providing updates on its therapeutic programs targeting pain.

Channel Therapeutics Corporation has completed its reincorporation from Delaware to Nevada through a merger with its wholly-owned subsidiary, effective November 18, 2024.

Channel Therapeutics Corporation has completed its reincorporation from Delaware to Nevada through a merger with its wholly-owned subsidiary, effective November 18, 2024.

Chromocell Therapeutics Corporation has increased its stock repurchase plan by $500,000 to a total of $750,000 and extended the plan's termination date to June 30, 2025, while also approving a reincorporation in Nevada and a name change to Channel Therapeutics Corporation.

Chromocell Therapeutics Corporation has authorized a stock repurchase plan of up to $250,000, believing its current stock price does not reflect the company's progress.

Chromocell Therapeutics Corporation has entered into agreements for a $750,000 convertible note and a $30 million committed equity financing facility to support its clinical programs.

Chromocell Therapeutics' CEO provided an update to stockholders, highlighting the company's recent IPO, development programs, and growth plans.